Myoscience, a California-based medical device company, completed patient enrollment in two prospective, randomized, placebo-controlled studies focused on relieving knee pain.
Here are six takeaways:
1. The MYO-1070 study evaluates post-surgical pain management for patients treated with iovera prior to undergoing a total knee replacement; 150 patients were enrolled, and the enrollment target was reached six weeks early.
2. The MYO-0946 study evaluates iovera as a temporary nerve block for patients with chronic knee pain due to osteoarthritis; 180 patients were enrolled.
3. Both studies measure the effect of using the FDA-cleared iovera treatment to freeze the peripheral nerves which transmit pain to the knee.
4. The iovera treatment provides an immediate nerve block that is a non-systematic, non-narcotic solution to blocking pain for an extended period of time.
5. The iovera treatment has been commercially available in the United States since March 2014.
6. Results of the studies will be available later this year.